A prospective, safety, efficacy and multicenter single-arm clinical trial of peritoneal metastatic adenocarcinoma pressurized abdominal aerosol chemotherapy (PIPAC)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500111035

Enrollment

Unknown

Registered

2025-10-24

Start date

2025-02-26

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with peritoneal metastatic adenocarcinoma originated from the stomach and colorectal organs

Interventions

The PIPAC treatment group:PIPAC treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with pathologically confirmed peritoneal metastatic adenocarcinoma originating from the stomach, colon, or rectum; 2. Any gender, age between 18 and 75 years; 3. At least one measurable tumor lesion according to RECIST 1.1 criteria; 4. ECOG performance status = 1.5 × 10^9/L, platelet count >= 80 × 10^9/L, hemoglobin >= 80 g/L, Biochemistry: total serum bilirubin 6 months; 9. Able to understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Subjects with digestive tract obstruction; 2.Subjects who rely solely on parenteral nutrition; 3.Subjects with compensated ascites and associated with decompensated ascites; 4.Subjects with severe abdominal cavity infection (manifestations of peritonitis); 5.Subjects with extensive peritoneal adhesions; 6.Subjects who simultaneously underwent tumor resection and digestive tract resection and reconstruction surgery; 7.Subjects with portal vein thrombosis combined; 8.History of allergy to chemotherapy drugs; 9.Those with serious diseases of the heart and lungs, liver and kidneys, blood system or mental health, and those who abuse drugs; 10.Pregnant or lactating women; 11.Patients who have participated in or are currently participating in other clinical trials within 3 months.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse reactions;Postoperative pain score (VAS score);Quality of life situation;	—

Secondary

Measure	Time frame
overall survival;Pathological remission rate (PRGS);	—

Countries

China

Contacts

Public ContactWang Guihua

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

ghwang@tjh.tjmu.edu.cn+86 150 7145 9503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026